Answers are grounded in this paper and cite their sources.
OBJECTIVE: To review the efficacy, safety, and available literature regarding the novel combination bioidentical product Bijuva, or 17β-estradiol/progesterone (17β-E/P), for the treatment of moderate to severe menopausal symptoms in cisgender females with an intact uterus. DATA SOURCES: . STUDY SELECTION AND DATA EXTRACTION: All articles with studies conducted in cisgender human females and in the English language were considered for review; 18 publications were included. DATA SYNTHESIS: In 1 phase 3 clinical study, 17β-E/P was proven to be effective at reducing the frequency and severity of vasomotor symptoms (VMS) at 12 weeks compared with placebo, and no cases of endometrial hyperplasia were observed over the 52-week safety study period. Menopausal women with an intact uterus were included in the study population. RELEVANCE TO PATIENT CARE AND PRACTICE: Concerns over content and safety of compounded bioidentical hormones have been raised by several professional societies. As women experience VMS of menopause, a desire for a Food and Drug Administration-regulated bioidentical combination product for the treatment of moderate to severe menopausal symptoms may be desirable. Given as a once-daily oral capsule at the dose of 1 mg estradiol/100 mg progesterone, 17β-E/P is approved for the treatment of VMS associated with menopause. CONCLUSIONS: 17β-E/P is a novel bioidentical product that is the first of its kind in the treatment of moderate to severe menopausal symptoms.
No takes yet. Share an insight, caveat, or question.
Woodis et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: